The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via interim final rule during the Trump administration to initiate a seven-year, nationwide, mandatory effort to test an alternative way for Medicare to pay for certain Medicare Part B single-source drugs and biologicals. CMS in August signaled its intent to end the model, for which AHA voiced support in an Oct. 11 letter to the agency by arguing that the rule’s “legal infirmities fell within three major categories: (1) failure to follow proper procedures in promulgating the rule, (2) exceeding statutory authority, and (3) constitutional violations.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services yesterday released a memo and timeline outlining how it will approach implementing the Inflation…
Headline
Price increases for over 1,200 drugs exceeded inflation between July 2021 and July 2022, including many drugs used to treat cancer and other chronic conditions…
Headline
The Centers for Medicare & Medicaid Services yesterday released premium and cost-sharing information for Medicare Advantage and Part D prescription drug…
Headline
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study…
Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…